NasdaqGS:KRYSBiotechs
Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed?
Krystal Biotech reported fourth-quarter 2025 net income of US$51.4 million and full-year net income of US$204.83 million, with both basic and diluted earnings per share increasing compared with the prior year.
Alongside these stronger earnings, the company is drawing heightened attention from Wall Street and industry events, as analysts reiterate positive views on its genetic medicines platform and leadership participates in high-profile healthcare conferences.
With this earnings momentum as...